Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

Study participants need to have been self-administering etanercept for greater than or equal
to 6 months prior to screening. You will be in this study for about 9 weeks. This includes a
4-week screening period and a 5-week treatment period.

Inclusion Criteria:

- Subject has diagnosis of RA or PsA and indicated for treatment with etanercept per the
current label, based on history.

- Subject is willing to self-inject per investigator judgement at screening.

- Subject has no known history of tuberculosis.

Exclusion Criteria:

- Latex allergy.

- Subject has any active infection (including chronic or localized infections) for which
anti-infectives were indicated within 4 weeks prior to first study dose of etanercept.

- Subject had prosthetic joint infection within 5 years of screening or native joint
infection within 1 year of screening.

- Other criteria may apply.